ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
ma420
|
391 |
84K |
12 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
391
|
84K
|
12
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
31K |
6 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
31K
|
6
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
31K |
7 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
31K
|
7
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
31K |
8 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
31K
|
8
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
31K |
7 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
31K
|
7
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
31K |
10 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
31K
|
10
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
31K |
6 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
31K
|
6
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
31K |
16 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
31K
|
16
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
31K |
5 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
31K
|
5
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
31K |
6 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
31K
|
6
|
|
ASX - By Stock
|
COV |
Re:
Ann: COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark
|
|
ma420
|
62 |
27K |
0 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
62
|
27K
|
0
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
31K |
5 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
31K
|
5
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Investor presentation
|
|
ma420
|
43 |
11K |
4 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
43
|
11K
|
4
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
31K |
9 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
31K
|
9
|
|
ASX - By Stock
|
COV |
Re:
Ann: COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark
|
|
ma420
|
62 |
27K |
1 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
62
|
27K
|
1
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
31K |
5 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
31K
|
5
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Company Analysis - Morgans
|
|
ma420
|
19 |
8.6K |
18 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
19
|
8.6K
|
18
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
ma420
|
391 |
84K |
14 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
391
|
84K
|
14
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Company Analysis - Morgans
|
|
ma420
|
19 |
8.6K |
4 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
19
|
8.6K
|
4
|
|
ASX - By Stock
|
CVB |
Re:
Ann: Sales Update for Q4 FY2024
|
|
ma420
|
23 |
8.2K |
4 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
23
|
8.2K
|
4
|
|
ASX - By Stock
|
CVB |
Re:
Ann: Sales Update for Q4 FY2024
|
|
ma420
|
23 |
8.2K |
1 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
23
|
8.2K
|
1
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
31K |
10 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
117
|
31K
|
10
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
31K |
6 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
117
|
31K
|
6
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
ma420
|
391 |
84K |
16 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
391
|
84K
|
16
|
|
ASX - By Stock
|
CVB |
Re:
Ann: Sales Update for Q4 FY2024
|
|
ma420
|
23 |
8.2K |
0 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
23
|
8.2K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor Briefings & Webinar Notice
|
|
ma420
|
81 |
24K |
13 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
81
|
24K
|
13
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
31K |
4 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
117
|
31K
|
4
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
31K |
5 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
117
|
31K
|
5
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
31K |
1 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
117
|
31K
|
1
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
31K |
3 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
117
|
31K
|
3
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
ma420
|
2.2K |
779K |
4 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
2.2K
|
779K
|
4
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
ma420
|
2.2K |
779K |
15 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
2.2K
|
779K
|
15
|
|
ASX - By Stock
|
COV |
Re:
Cleo Media Thread
|
|
ma420
|
9 |
4.9K |
2 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
9
|
4.9K
|
2
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Investor presentation
|
|
ma420
|
43 |
11K |
4 |
07/07/24 |
07/07/24 |
ASX - By Stock
|
43
|
11K
|
4
|
|
ASX - By Stock
|
COV |
Re:
Ann: Cleo Commences US Regulatory Process with FDA
|
|
ma420
|
19 |
8.2K |
2 |
07/07/24 |
07/07/24 |
ASX - By Stock
|
19
|
8.2K
|
2
|
|
ASX - By Stock
|
SNT |
SNT - General Discussions
|
|
ma420
|
117 |
31K |
8 |
06/07/24 |
06/07/24 |
ASX - By Stock
|
117
|
31K
|
8
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Distinguished Oncologist Daniel Von Hoff Joins as Consultant
|
|
ma420
|
168 |
48K |
1 |
05/07/24 |
05/07/24 |
ASX - By Stock
|
168
|
48K
|
1
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Investor presentation
|
|
ma420
|
43 |
11K |
3 |
05/07/24 |
05/07/24 |
ASX - By Stock
|
43
|
11K
|
3
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Investor presentation
|
|
ma420
|
43 |
11K |
11 |
05/07/24 |
05/07/24 |
ASX - By Stock
|
43
|
11K
|
11
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Investor presentation
|
|
ma420
|
43 |
11K |
5 |
05/07/24 |
05/07/24 |
ASX - By Stock
|
43
|
11K
|
5
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Investor presentation
|
|
ma420
|
43 |
11K |
4 |
05/07/24 |
05/07/24 |
ASX - By Stock
|
43
|
11K
|
4
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Distinguished Oncologist Daniel Von Hoff Joins as Consultant
|
|
ma420
|
168 |
48K |
5 |
05/07/24 |
05/07/24 |
ASX - By Stock
|
168
|
48K
|
5
|
|
ASX - By Stock
|
COV |
Re:
Ann: Cleo Commences US Regulatory Process with FDA
|
|
ma420
|
19 |
8.2K |
1 |
05/07/24 |
05/07/24 |
ASX - By Stock
|
19
|
8.2K
|
1
|
|
ASX - By Stock
|
COV |
Re:
Ann: Cleo Commences US Regulatory Process with FDA
|
|
ma420
|
19 |
8.2K |
1 |
05/07/24 |
05/07/24 |
ASX - By Stock
|
19
|
8.2K
|
1
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Investor presentation - equity raising
|
|
ma420
|
10 |
3.1K |
1 |
05/07/24 |
05/07/24 |
ASX - By Stock
|
10
|
3.1K
|
1
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Investor presentation - equity raising
|
|
ma420
|
10 |
3.1K |
2 |
05/07/24 |
05/07/24 |
ASX - By Stock
|
10
|
3.1K
|
2
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Distinguished Oncologist Daniel Von Hoff Joins as Consultant
|
|
ma420
|
168 |
48K |
12 |
05/07/24 |
05/07/24 |
ASX - By Stock
|
168
|
48K
|
12
|
|
ASX - By Stock
|
ILA |
Re:
Ann: Non-binding term sheet signed with BioCryst
|
|
ma420
|
41 |
9.3K |
2 |
05/07/24 |
05/07/24 |
ASX - By Stock
|
41
|
9.3K
|
2
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Investor presentation - equity raising
|
|
ma420
|
10 |
3.1K |
2 |
04/07/24 |
04/07/24 |
ASX - By Stock
|
10
|
3.1K
|
2
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race In-person Investor Briefing Invitation Perth
|
|
ma420
|
130 |
39K |
6 |
04/07/24 |
04/07/24 |
ASX - By Stock
|
130
|
39K
|
6
|
|